Axsome Therapeutics (AXSM) Other Accumulated Expenses (2015 - 2026)

Axsome Therapeutics (AXSM) has 11 years of Other Accumulated Expenses data on file, last reported at $12.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 54.88% year-over-year to $12.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (up 54.88% YoY), and the FY2025 full-year result was $7.9 million, down 20.65% from the prior year.
• Other Accumulated Expenses improved to $12.2 million in Q1 2026, from $7.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $12.2 million in Q1 2026 to a low of $705583.0 in Q2 2022.
• A 5-year average of $6.1 million and a median of $6.3 million in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 1052.1% in 2023 and tumbled 50.94% in 2024, its largest moves.
• Tracing AXSM's Other Accumulated Expenses over 5 years: stood at $1.6 million in 2022, then jumped by 266.54% to $5.9 million in 2023, then soared by 68.01% to $10.0 million in 2024, then decreased by 20.65% to $7.9 million in 2025, then soared by 55.0% to $12.2 million in 2026.
• Business Quant data shows AXSM's Other Accumulated Expenses at $12.2 million in Q1 2026, $7.9 million in Q4 2025, and $7.0 million in Q3 2025.